KNOW THE FACTS ABOUT FLU

Flu places a significant burden on the health and economy of the United States.1

CDC estimates* that from October 1, 2024, through May 17, 2025, there have been1:

  • Between 47 and 82 Million Flu Illnesses
  • Between 21 and 37 Million Flu Medical Visits
  • Between 610,000 and 1.3 Million Flu Hospitalizations
  • Between 27,000 and 130,000 Flu Deaths

*Because influenza surveillance does not capture all cases of flu that occur in the US, CDC provides these estimated ranges to better reflect the larger burden of influenza. These estimates are calculated based on data collected through CDC's Influenza Hospitalization Surveillance Network (FluSurv-NET) and are preliminary.1

Annual flu vaccination goals remain unreached for both children and adults 18-64 years of age2-4

A 70% rate of annual flu vaccination in children 6 months to 17 years of age is the CDC's Healthy People 2030 goal, yet only 49.2% were vaccinated in the 2024-2025 season.2,3†

2024-2025 flu vaccine estimated coverage rates for children by age group3

  • Flu Vaccine Estimated Coverage Rates for Children from 6 Months to 4 Years Old
  • Flu Vaccine Estimated Coverage Rates for Children from 5 to 12 Years Old
  • Flu Vaccine Estimated Coverage Rates for Children from 13 to 17 Years Old
Additional options for influenza vaccination of children, including use of noninjectable vaccines, may help improve coverage5

CDC's Healthy People 2030 objective is a 70% rate of annual flu vaccination in adults 18 to 49 years of age, yet only 36.3% were vaccinated in the 2024-2025 season.2,4†

2024-2025 flu vaccination estimated coverage rates for adults by age group4

Flu Vaccine Estimated Coverage Rates for Adults from 18 to 49 Years Old Flu Vaccine Estimated Coverage Rates for Adults from 18 to 49 Years Old

CDC recommends annual flu vaccination for everyone 6 months and older with any licensed, age-appropriate flu vaccine (IIV, RIV, LAIV, ccIIV, HD-IIV, allV). For those younger than 65 years, CDC does not preferentially recommend one vaccine over another.6

†Data published as of April 26, 2025.

aIIV=adjuvanted inactivated influenza vaccine; ccIIV=cell culture–based inactivated influenza vaccine; CDC=Centers for Disease Control and Prevention; HD-IIV=high-dose inactivated influenza vaccine; IIV=inactivated influenza vaccine; LAIV=live attenuated influenza vaccine; RIV=recombinant influenza vaccine.

Important Safety Information

OPEN

Important Safety Information

  • Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
  • When administered in a healthcare setting, appropriate medical treatment must be immediately available to manage potential anaphylactic reactions. When self-administered or administered by a caregiver, immediate medical attention should be sought if the vaccine recipient experiences symptoms of an allergic reaction
  • In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
  • Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of potential benefits and risks
  • The effectiveness of FLUMIST has not been studied in immunocompromised persons
  • The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
  • FLUMIST may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever >100 °F (children
    ages 2-6 years), and sore throat (adult ages 18-49 years)

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

Please see full Prescribing Information, including Patient Information and Instructions for Use.

You may report side effects related to AstraZeneca products .

References:
  1. FLUMIST Prescribing Information.
  2. Guidice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev. 2006;58(1):68-89.
  3. Data on File, REF-263898. AstraZeneca Pharmaceuticals LP.
References:
  1. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2024–25 influenza season. MMWR Morb Mortal Wkly Rep. 2024;73(5):1-25. doi:10.15585/mmwr.rr7305a1
  2. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2024–2025: policy statement. Pediatrics. 2024;154(4):e2024068507. doi:10.1542/peds.2024-068507
  3. Vaccine pricing. Centers for Medicare & Medicaid Services (CMS). Accessed June 10, 2025. https://www.cms.gov/medicare/payment/part-b-drugs/vaccine-pricing
References:
  1. FLUMIST Prescribing Information.
  2. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices—United States, 2024–25 influenza season. MMWR Morb Mortal Wkly Rep. 2024;73(5):1–25. doi:10.15585/mmwr.rr7305a1
  3. Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices–United States, 2023-24 influenza season. MMWR Morb Mortal Wkly Rep. 2023;72(No. RR-2):1-25. doi:10.15585/mmwr.rr7305a1rr7202a1
  4. Influenza vaccine products for the 2024-2025 influenza season. Accessed June 10, 2025. https://www.immunize.org/wp-content/uploads/catg.d/p4072.pdf
References:
  1. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev. 2006;58(1):68-89. doi:10.1016/j.addr.2005.12.003
  2. FLUMIST Prescribing Information.
  3. Vaccines and immunizations: Vaccine administration. Centers for Disease Control and Prevention. Accessed March 20, 2025. https://www.cdc.gov/vaccines/hcp/imz-best-practices/vaccine-administration.html?CDC_AAref_Val=https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html#cdc_report_pub_study_section_2-route-of-administration
  4. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 2002;15(2):295-323. doi:10.1089/08828240260066242
Reference:
  1. FLUMIST Prescribing Information.
References:
  1. UK Health Security Agency. Surveillance of influenza and other seasonal respiratory viruses in the UK, winter 2022 to 2023. Accessed April 7, 2025. https://www.gov.uk/government/statistics/annual-flu-reports/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-the-uk-winter-2022-to-2023
  2. Kissling E, Maurel M, Emborg HD, et al. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. Euro Surveill. 2023;28(21):2300116. doi:10.2807/1560-7917.ES.2023.28.21.2300116
  3. McLean HQ, Petrie JG, Hanson KE, et al. Interim estimates of 2022-23 seasonal influenza vaccine effectiveness–Wisconsin, October 2022–February 2023. MMWR Morb Mortal Wkly Rep. 2023;72(8):201-205. doi:10.15585/mmwr.mm7208a1
  4. UK Health Security Agency. Surveillance of influenza and other seasonal respiratory viruses in the UK, winter 2023 to 2024. Accessed April 25, 2025. https://www.gov.uk/government/statistics/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-the-uk-winter-2023-to-2024
  5. Frutos AM, Price AM, Harker E, et al; CDC Influenza Vaccine Effectiveness Collaborators. Interim estimates of 2023-24 seasonal influenza vaccine effectiveness–United States. MMWR Morb Mortal Wkly Rep. 2024;73(8):168-174. doi:10.15585/mmwr.mm7308a3
  6. Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices–United States, 2023-24 influenza season. MMWR Morb Mortal Wkly Rep. 2023;72(No. RR-2):1-25. doi:10.15585/mmwr.rr7202a1
  7. Rose AM, Lucaccioni H, Marsh K, et al. Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025. Euro Surveill. 2025;30(7):2500102. doi:10.2807/1560-7917.ES.2025.30.7.2500102
  8. Zhu S, Quint J. Interim influenza vaccine effectiveness against laboratory-confirmed influenza, California, October 2024-January 2025. Advisory Committee on Immunization Practices Meeting. Accessed June 17, 2025. https://www.cdc.gov/acip/downloads/slides-2025-04-15-16/03-zhu-influenza-508.pdf
  9. Live attenuated influenza vaccine [LAIV] (the nasal spray flu vaccine). Centers for Disease Control and Prevention. Accessed March 4, 2025. https://www.cdc.gov/flu/vaccine-types/nasalspray.html?CDC_AAref_Val=https://www.cdc.gov/flu/prevent/nasalspray.htm
References:
  1. FLUMIST Prescribing Information.
References:
  1. Newall M, Morris C. Expanding flu vaccine. Ipsos. Accessed April 8, 2025. https://www.ipsos.com/en-us/news-polls/expanding-flu-vaccine
References:
  1. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2024-25 influenza season. MMWR Morb Mortal Wkly Rep. 2024;73(5):1-25. doi:10.15585/mmwr.rr7305a1
  2. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2024–2025: policy statement. Pediatrics. 2024;154(4):e2024068507. doi:10.1542/peds.2024-068507
  3. Healthy People 2030. Increase the proportion of people who get the flu vaccine every year—IID-09. Office of Disease Prevention and Health Promotion, US Dept of Health and Human Services. Accessed April 7, 2025. https://odphp.health.gov/healthypeople/objectives-and-data/about-objectives/healthy-people-2030-objectives-and-measures
References:
  1. FLUMIST Prescribing Information.
  2. Update on influenza B/Yamagata surveillance. Centers for Disease Control and Prevention. Accessed April 7, 2025. https://stacks.cdc.gov/view/cdc/134669
  3. Summary minutes of 183rd Vaccines and Related Biological Products Advisory Committee. Virtual; October 5, 2023: FDA-2023-N-3300. US Food and Drug Administration. Accessed April 7, 2025. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-october-5-2023-meeting-announcement?utm_medium=email&utm_source=govdelivery
  4. Types of influenza viruses. Centers for Disease Control and Prevention. Accessed March 19, 2025. https://www.cdc.gov/flu/about/viruses-types.html
  5. Appiah GD, Blanton L, D’Mello T, et al; Centers for Disease Control and Prevention (CDC). Influenza activity—United States, 2014–15 season and composition of the 2015–16 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2015;64(21):583-590.
  6. Davlin SL, Blanton L, Kniss K, et al. Influenza activity—United States, 2015–16 season and composition of the 2016–17 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2016;65(22):567-575. doi:10.15585/mmwr.mm6522a3
  7. Blanton L, Alabi N, Mustaquim D, et al. Update: influenza activity in the United States during the 2016–17 season and composition of the 2017–18 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(25):668-676. doi:10.15585/mmwr.mm6625a3
  8. Garten R, Blanton L, Elal AIA, et al. Update: influenza activity in the United States during the 2017–18 season and composition of the 2018–19 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2018;67(22):634-642. doi:10.15585/mmwr.mm6722a4
  9. Xu X, Blanton L, Elal AIA, et al. Update: influenza activity in the United States during the 2018–19 season and composition of the 2019–20 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2019;68(24):544-551. doi:10.15585/mmwr.mm6824a3
  10. US virologic surveillance. Centers for Disease Control and Prevention. Accessed April 7, 2025. https://www.cdc.gov/flu/weekly/weeklyarchives2019-2020/Week14.htm
  11. Olsen SJ, Winn AK, Budd AP, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic—United States, 2020–2021. MMWR Morb Mortal Wkly Rep. 2021;70(29):1013-1019. doi:10.15585/mmwr.mm7029a1
  12. FluView summary ending on October 1, 2022. Centers for Disease Control and Prevention. Accessed April 7, 2025. https://www.cdc.gov/flu/weekly/weeklyarchives2021-2022/week39.htm
  13. Weekly U.S. influenza surveillance report key updates for week 23 ending June 10, 2023. Centers for Disease Control and Prevention. Accessed April 7, 2025. https://stacks.cdc.gov/view/cdc/129922
  14. FluView summary ending on June 22, 2024. Centers for Disease Control and Prevention. Accessed April 7, 2025. https://www.cdc.gov/flu/weekly/weeklyarchives2023-2024/week25.htm
  15. Weekly US influenza surveillance report: key updates for week 21, ending May 24, 2025. Centers for Disease Control and Prevention. Accessed June 19, 2025. https://www.cdc.gov/fluview/surveillance/2025-week-21.html
References:
  1. FLUMIST Prescribing Information.
  2. Hayden FG, Palese P. Influenza virus. In: Richman DD, Whitley FJ, Hayden FG, eds. Clinical Virology. 4th ed. ASM Press; 2017:1009-1058.
  3. World Health Organization. The Immunological Basis for Immunization Series. Module 23: Influenza Vaccines. World Health Organization, Dept of Immunization, Vaccines and Biologicals; 2017:1-63.
  4. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 2002;15(2):295-323. doi:10.1089/08828240260066242
  5. Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respir Viruses. 2008;2:193-202. doi:10.1111/j.1750-2659.2008.00056.x
  6. Wodi PA, Morelli V. Chapter 1: Principles of Vaccination. Centers for Disease Control and Prevention. Accessed April 8, 2025. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-1-principles-of-vaccination.html
  7. Vaccine administration. Centers for Disease Control and Prevention. Accessed April 8, 2025. https://www.cdc.gov/vaccines/hcp/imz-best-practices/vaccine-administration.html?CDC_AAref_Val=https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html
References:
  1. FLUMIST Prescribing Information.
  2. Wodi PA, Morelli V. Chapter 1: Principles of Vaccination. Centers for Disease Control and Prevention. Accessed April 8, 2025. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-1-principles-of-vaccination.html
  3. How flu spreads. Centers for Disease Control and Prevention. Accessed April 8, 2025. www.cdc.gov/flu/about/disease/spread.htm
  4. Different types of flu vaccines. Centers for Disease Control and Prevention. Accessed April 8, 2025. https://www.cdc.gov/flu/vaccine-types/?CDC_AAref_Val=https://www.cdc.gov/flu/prevent/different-flu-vaccines.htm
  5. Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine. 2011;29(50):9391-9397. doi:10.1016/j.vaccine.2011.09.109
  6. Block SL, Falloon J, Hirschfield JA, et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J. 2012;31(7):745-751. doi:10.1097/INF.0b013e31825687b0
  7. Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011;204(6):845-853. doi:10.1093/infdis/jir436
  8. Ambrose CS, Wu X, Jones T, Mallory RM. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine. 2012;30(48):6794-6801. doi:10.1016/j.vaccine.2012.09.018
  9. Barría MI, Garrido JL, Stein C, et al. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis. 2013;207(1):115-124. doi:10.1093/infdis/jis641
  10. Basha S, Hazenfeld S, Brady RC, Subbramanian RA. Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin. Hum Immunol. 2011;72(6):463-469. doi:10.1016/j.humimm.2011.03.001
  11. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis. 2000;181(3):1133-1137. doi:10.1086/315323
References:
  1. FLUMIST Prescribing Information.
  2. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2024–25 influenza season. MMWR Morb Mortal Wkly Rep. 2024;73(5):1-25. doi:10.15585/mmwr.rr7305a1
  3. Ask the experts: influenza: live attenuated influenza vaccine (LAIV) issues. Immunize.org. Accessed June 18, 2025. https://www.immunize.org/ask-experts/topic/influenza/laiv-issues/
  4. Vaccines and immunizations: Vaccine administration. Centers for Disease Control and Prevention. Accessed March 20, 2025. https://www.cdc.gov/vaccines/hcp/imz-best-practices/vaccine-administration.html?CDC_AAref_Val=https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html#cdc_report_pub_study_section_2-route-of-administration
  5. Data on File, REF-263898. AstraZeneca Pharmaceuticals LP.
  6. Key facts about seasonal flu vaccine. Centers for Disease Control and Prevention. Accessed April 8, 2025. https://www.cdc.gov/flu/vaccines/keyfacts.html?CDC_AAref_Val=https://www.cdc.gov/flu/prevent/keyfacts.htm
  7. Live attenuated influenza vaccine [LAIV] (the nasal spray flu vaccine). Centers for Disease Control and Prevention. Accessed April 8, 2025. https://www.cdc.gov/flu/vaccine-types/nasalspray.html?CDC_AAref_Val=https://www.cdc.gov/flu/prevent/nasalspray.htm
  8. Safety of influenza vaccines. Centers for Disease Control and Prevention. Accessed June 10, 2025. https://archive.cdc.gov/#/details?q=safety%20of%20influenza%20vaccines&start=0&rows=10&url=https://www.cdc.gov/flu/professionals/acip/safety-vaccines.htm
References:
  1. Preliminary estimated flu disease burden 2024-2025 flu season. Centers for Disease Control and Prevention. Accessed April 7, 2025. https://archive.cdc.gov/#/details?url=https://www.cdc.gov/flu-burden/php/data-vis/2024-2025.html
  2. Healthy People 2030. Increase the proportion of people who get the flu vaccine every year—IID-09. Office of Disease Prevention and Health Promotion, US Dept of Health and Human Services. Accessed April 7, 2025. https://odphp.health.gov/healthypeople/objectives-and-data/about-objectives/healthy-people-2030-objectives-and-measures
  3. Influenza vaccination coverage, children 6 months through 17 years, United States. Centers for Disease Control and Prevention. Accessed April 7, 2025. https://www.cdc.gov/fluvaxview/dashboard/children-vaccination-coverage.html
  4. Influenza vaccination coverage and intent for vaccination, adults 18 years and older, United States. Centers for Disease Control and Prevention. Accessed April 7, 2025. https://www.cdc.gov/fluvaxview/dashboard/adult-coverage.html
  5. Newall M, Morris C. Expanding flu vaccine. Ipsos. Accessed April 8, 2025. https://www.ipsos.com/en-us/news-polls/expanding-flu-vaccine
  6. Clinical guidance for influenza vaccination. Centers for Disease Control and Prevention. Accessed April 7, 2025. https://www.cdc.gov/flu/hcp/vax-summary/?CDC_AAref_Val=https://www.cdc.gov/flu/professionals/vaccination/vax-summary.htm
Reference:
  1. FLUMIST Prescribing Information.

Stay updated on FLUMIST

Please fill out the form below. The information you submit will be governed by our 
Privacy Notice.

The processing of this request requires the use of cookies and website tracking technologies that are available on this website. By clicking Submit, I agree to the storage of these cookies and website tracking technologies on my device. See our Privacy Policy for more information.

AstraZeneca is committed to helping healthcare professionals provide appropriate care to their patients. Please provide us with the following information so that we can keep your records up to date and can send you any information that you request. If in the future you no longer want to receive health-related materials from AstraZeneca, please call 1-800-236-9933. Please visit www.azprivacynotice.com to review our Privacy Notice.